Newly Activated Clinical Trials

This is a listing of clinical trials recently activated by the University of Illinois Cancer Center Clinical Trials Office for patient enrollment.

Click the study links below to learn details regarding the studies on You can also search for other clinical trials on our website. For more information or questions about a study, email or call 312-355-5112.

Protocol Title:  AMG2021-0004: A Randomized, Open-label, Phase 3 Study of Tarlatamab Compared with Standard of Care in Subjects with Relapsed Small Cell Lung Cancer after Platinum-based First Line Chemotherapy

Sponsor: Amgen

Principal Investigator: Frank Weinberg MD, PhD

Protocol Title: GS-US-595-6184: A Randomized, Open-Label, Phase 3 Study of Adjuvant Sacituzumab Govitecan and Pembrolizumab Versus Treatment of Physician’s Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy

Sponsor: Gilead Science, INC.

Principal Investigator: Abiola Ibraheem, MD

Photo of Abiola Ibraheem, MD

Protocol Title: RiMO-401CL23-001:  Phase I Dose-Escalation Study of RiMO-401 With Radiation in Advanced Tumors

Sponsor: Coordination Pharmaceuticals

Principal Investigator: Oana Danciu, MD

Translate »